The Estée Lauder Companies showcases latest data on oxidative damage, skin barrier function, hyperpigmentation, and natural extracts at the 2022 Society for Investigative Dermatology Annual Meeting
Meeting Announcement
The Estée Lauder Companies Inc. (NYSE: EL) research and development (R&D) team will present data that provides new insights in priority areas of research including epidermal function and skin barrier, fermentation, skin aging and pigmentation. The Estée Lauder Companies’ R&D team is a global leader in understanding the factors that impact our skin, with R&D playing a key role in gathering insights on how the skin appears and behaves. Scientists from the Estée Lauder Companies R&D and brand research teams will present their latest findings at the 2022 Society for Investigative Dermatology (SID) Annual Meeting in Portland, Oregon, from May 18-21. The SID Annual Meeting is a top dermatology conference that allows an expansive community of scientists and researchers to share the latest advancements in the skin care field.
Leading European experts are gathering for a research integrity training and marking the end of the Horizon 2020 research project Path2Integrity
The 27th North American Meeting of the North American Catalysis Society (NAM27), the premier scientific event in the field of catalysis research and development in 2022, will be held May 22-27, 2022 (Hilton Midtown, Manhattan, NY, USA). The meeting is a forum for the discussion of relevant technological issues and cutting-edge research on catalysis. Catalysts are materials that accelerate chemical reactions for manufactured products (energy, chemicals, sustainable energy and green chemicals, environmental solutions and pharmaceuticals) that are related to approximately 25 percent of USA GDP and play a significant role in the economies of other developed countries. The meeting will focus on technological challenges, breakthrough discoveries, and state-of-the-art research in catalysis.
Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement and enabled reduced glucocorticoid use in ANCA-associated vasculitis patients participating in the phase 3 ADVOCATE trial. Study results were published at the ATS 2022 international conference. The study was a subgroup analysis of results from the larger trial, which led to FDA approval of avacopan.
One of the legacies of “redlining” may be higher incidence and mortality rates of COVID-19 affecting the largely minority and poor residents of these neighborhoods, according to research published at the ATS 2022 international conference. ” Redlining is a Great Depression-era federal policy in which neighborhoods with large ethnic/racial minority groups were denied federal resources.
A virtual event celebrating diverse voices in art, film, theatre and games is being hosted by Staffordshire University this week – and there's still time to book your place! The second edition of interdisciplinary conference and festival ‘Communities and Communication 2022 takes place over two days from Thursday 19 to Friday 20 June, bringing together creators, academics and researchers from across the globe. The conference received more than 3,000 submissions from nearly 130 countries and the programme features contributions from musicians, artists, filmmakers and researchers from a range of disciplines. The event comprises eight panel discussions and numerous film screenings, including presentations on indigenous film production, deaf communities, virtual worlds, and much more.
May 17, 2022 – People living with schizophrenia and other psychosis spectrum disorders are too often misunderstood or ignored – by the public, by the healthcare system – and current treatments are outdated and often cause significant side effects. On Nov. 2, the schizophrenia community will finally have the spotlight, as those living with the condition and their family members share their treatment needs and concerns with drug developers and FDA staff who review new drug applications. The Externally-Led Patient Focused Drug Development (PFDD) meeting – “Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive” – offers the chance to make what matters to those living with the neurobiological brain disease a higher priority in drug development and the FDA review process.
The first study to look at follow-up for patients deemed at high risk for lung cancer after CT screening found that 47 percent delayed follow-up care, according to research published at the ATS 2022 international conference.
Paris, France. 17 May 2022. May 17th is World Hypertension Day whose theme “Measure Your Blood Pressure Accurately, Control It, Live Longer” is aimed at increasing awareness of hypertension worldwide. Besides awareness, effective control of hypertension remains low in the general population. At EuroPCR 2022, the Global SYMPLICTY Registry and 3 ongoing trials – SPYRAL-HTN ON MED, RADIANCE-HTN SOLO and TRIO – will further focus on expanding experience in effective device-based treatments for hypertension using renal denervation.
At the Science7 Dialogue Forum in Berlin/Germany on Tuesday, 31 May, the science academies of the G7 states will publish science-based statements on topics on this year's agenda of the G7 summit at Schloss Elmau/Germany. Key topics of the statements prepared under the leadership of the Leopoldina are the effects of climate change on polar regions and ocean, measures for decarbonisation, the development of antiviral drugs for pandemic preparedness and the need for a One Health approach to address zoonoses and antimicrobial resistance. Representatives of the national science academies will hand over the statements to the German government during the Science7 Dialogue Forum. Media representatives are invited to attend the event and the associated science conference. Prior registration is required.
St. Jude Children’s Research Hospital scientists will discuss research on cellular therapies for pediatric cancer and more at the annual gathering of the professional society for gene and cellular therapy researchers.
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo, according to research published at the ATS 2022 international conference. The study showed that nearly half of those enrolled achieved complete response to treatment across measures of exacerbation reduction, asthma control, lung function, and clinician assessment.